Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 167.50 165.00 170.00 167.50 167.50 167.50 1,000 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 4526 to 4541 of 6675 messages
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older
DateSubjectAuthorDiscuss
06/5/2019
10:06
The same endless drivle. I did a quick check bronxville has been warning about Amryt since it was trading close to 20p and you have been deriding him all the way down to 12p. Oh and the poor little old pensioner routine is getting tedious as well.
chica1
05/5/2019
16:59
That arch conspiracy theorist, Bronxville, on the lse bb is trying to imply that Amryt's prediction of H2 2019 for the issue of the AP101 TOP-LINE DATA READ OUT has now drifted out to February 2022 because the clinicaltrials.gov web site says that is the expected date for the completion of the American AP101 trial and hence FDA approval (if the trial is deemed to be successful). I've news for you, Bronxville! Amryt have NEVER predicted that they are hoping for FDA approval in H2 2019. Have a look at the Amryt RNS's to see if you can find any such prediction. I can't! What Amryt are predicting for H2 2019 is the top-line data read out! BIG DIFFERENCE! I'm afraid you'll have to find some other stick with which to beat Amryt. PS Whether Amryt fulfil that H2 2019 prediction, or if it drifts into H1 2020, I have no idea. I treat my small shareholding in Amryt as a punt. A pure gamble on the success, or otherwise, of AP101. However if AP101 proves to be a failure for treating EB I'm hopeful that the existence of Lojuxta and AP103 will limit too much of a drop in the AMYT share price (which will hopefully be significantly higher by then on speculative investor interest). We will be in H2 2019 in less than a month and I'm hopeful that the AMYT share price will then start to rise in anticipation of the top-line data read out. I've got just under 15k of Amryt shares. I might increase that to 50k once we get into H2 2019 and the AMYT share price (hopefully) starts to rise. I'll still treat that 50k as a punt, a pure gamble, but with limited downside if AP101 turns out to be a dud.
papillon
04/5/2019
20:52
He thrives on confrontation.Probably undiagnosed Paranoid Personality Disorder. The other guy is doing work informing people and has been warning about Amryt for months.
chica1
03/5/2019
23:20
mdalos1 3 May '19 - 19:10 - 3 of 3 (Filtered) Bronxville Posts: 916 Opinion: No Opinion Price: 12.50 RE: Clinicaltrials.gov Today 18:53 Papillion the whole goal of the trial was getting FDA approval not EMA approval. They already have EMA approval for partial thickness wounds but they decided they needed FDA approval for EB to make Episalvan viable. My question is why so long Feb 2022 it is almost 3 years? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Whilst they have EMA approval for PTW's they DO NOT have EMA approval for EB, Bronxville. So the "goal of the (EASE) trial" is to gain both EMA & FDA approval, otherwise why would AMYT being conducting trials in Europe! I think you are being illogical, Bronxville, in saying it's solely to gain FDA approval. Why wouldn't AP101 be "viable" as a treatment for EB without FDA approval? After all AMYT can't sell Lojuxta in the America's (including the USA) and Japan because AMYT's license doesn't include those areas yet it's "viable" for AMYT to sell it in the rest of the world. Of course it's important to gain FDA approval because the USA is a big potential market for an effective EB treatment.
papillon
03/5/2019
18:28
Read this RNS, Bronxville. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Amryt-receives-IND-approval-from/78220498 Your February 2002 date only relates to the phase III AP101 trials being conducted in the USA. Trials were going ahead globally (as the RNS states) before the trials started in the USA. It just means that European approval will be received before approval in the USA if AP101 is deemed successful.
papillon
03/5/2019
11:50
Bronxville Posts: 912 Opinion: No Opinion Price: 12.50 Clinicaltrials.gov Today 09:22 Estimated AP101 study completion date February 2022 Curiousor and Curiousor >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> No it's not, curious, Bronxville as you well know! (learn to spell by the way!). This February 2022 completion date applies only to the phase III trials underway in the USA. hTTps://clinicaltrials.gov/ct2/show/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1 hTTps://clinicaltrials.gov/ct2/show/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1#contacts hTTps://clinicaltrials.gov/ct2/show/study/NCT03068780?term=amryt&cond=Epidermolysis+bullosa&cntry=GB&rank=1&show_locs=Y#locn PS. Have a look at this video, Bronxville. Top line data for AP101 expected H2 2019. Stop spreading lies, Bronxville! hTTps://www.ukinvestorshow.com/videos/amryt-pharma-plc/
papillon
03/5/2019
10:44
View Amryt Pharma's talk at The Global Group UK Investor Show: https://www.ukinvestorshow.com/videos/amryt-pharma-plc/
leeroy jenkins
02/5/2019
23:53
So tight Bollinger Bands get you excited, bazworth! :-). I wonder if there is such a thing as a porn site showing videos of tight Bollinger Bands? cbdrelief. FILTERED. He's made 603 posts since joining ADVFN on the 27/4/2019. That's 603 posts in less than a week. Apparently all on the same subject; the ramping of HNR on every ADVFN bb! Look at his posting history. Obviously ramping HNR is cbdrelief;s full time employment! LOL. It's unbelievable the frauds and conmen you get on these bb's. Why do ADVFN allow such blatant ramping to go unchecked?
papillon
02/5/2019
22:45
I adore tight Bollinger Bands! Let’s hope we spring free with huge upward momentum! Wake me up when we get started!
bazworth
02/5/2019
22:35
Tight Bollinger Bands, a rising RSI and the share price currently resting on support. free stock charts from uk.advfn.com
papillon
01/5/2019
15:27
I wouldn't want to share a room with MADLOSS, Tiananmen, because I'm told he smells. LOL I will continue to have small top ups in AMYT in the coming months because I think it is a good gamble in the lead up to the AP101 final phase III trial results irrespective of whether the trial results are deemed successful, or unsuccessful. I just think the AMYT Mkt Cap is currently too low bearing in mind the possibility of the phase III trial being deemed successful hence leading to the shares being significantly rerated and the fact that AMYT already has a revenue generating drug, Lojuxta, which is capable of significant growth. There is also the possibility (remote?) of another Lojuxta type licensing deal being struck. PS I particularly liked this bit in last months final results RNS: "Revenue growth has been further strengthened by a 118% increase in quarterly revenues from Saudi Arabia from Q4 2018 to Q1 2019." after initial orders where received from Saudi Arabia in Q4 2018. It has been mentioned before in an RNS that those of Middle East origin are more genetically pre disposed to suffer from HoFH so Saudi Arabia is a potentially big market for Lojuxta relative to other areas of the world. Consequently I'm hopeful that the current AMYT Mkt Cap is fully supported by Lojuxta and that AP101 and AP103 potential is being given negligible (or even no) value in the current Mkt Cap. So I see AMYT as a very tempting gamble at the current so on the prospects for AP101 and AP103 and with limited downside because of Lojuxta. That's my opinion. MADLOSS and purple may have different opinions, but I don't take notice of pumpers and dumpers like them. I use my own judgement. It's my money and I'll gamble with it as I see fit. They can stuff their opinions up their you know where!
papillon
01/5/2019
14:19
mdalos1 1 May '19 - 13:34 - 4415 of 4416 0 0 0 I'm puzzled Flutterby Given that at one point you possibly had around £6k locked in and were well underwater, then claimed you'd averaged down/topped up over time to the point that you unlocked yourself from that paper loss after a particular peak some months ago... AND given your sentiment about this Business, its Plans, timescales and indebtedness changed very noticeably throughout that stressful period... why are you still invested at all AND why would you start putting yourself back into as precarious a situation as you were previously in ? You already know nothing new's happening here and unlikely to happen for months. You already know it's MCAP is at best about right, all things considered. You should already know the SP's going to continue to slide. No Fool like an old Fool ???? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> You're puzzled, MADLOSS, because you're an idiot. As I posted at the time I significantly increased my AMYT stake to around £6k during December when the share price was under 13p. I admit I had shares bought at over 20p, but I only buy in circa £500 lots. Also my original bet, back in early 2015, was when the company was a "cash shell" and called FAST. The bet was made at just over 2p; equivalent to circa 17p after allowing for the 1 for 8 consolidation. I sold all of my AMYT shares, save for token 2,000, for circa 16p earlier this year. All recorded on this bb at the time. You're BORING me MADLOSS, so I've filtered you. Goodbye and good riddance. You're like purple11. A fantasist.
papillon
01/5/2019
13:48
You two need to get a room!
tiananmen
01/5/2019
11:40
Had a small top up first thing this morning (£600). Showing up as a sell on the financial web sites. Chart is beginning to look interesting.
papillon
30/4/2019
22:35
Back in early December 2018, mdalos, before the interim update, you reckoned that the AP101 interim trial news had an 86% chance of being UNSUCCESSFUL. mdalos1 - 10 Dec 2018 - 22:30:35 - 3841 of 3842 Amryt Pharma - AMYT I suggested the share price might go to 8.75p based on bad Trial news this quarter. I suggested the share price might go to around 18.75p on much better Trial news this quarter. I suggested there's a >50% and maybe as high as 86% chance of the Trial news not being at all favourable. mdalos1 5 Dec '18 - 23:19 - 3796 of 3797 0 0 0 8.75p beckons mdalos1 4 Dec '18 - 20:32 - 3776 of 3783 0 0 0 I told you this about the likely new News many months ago you FOOL... and yet you also don't get how there's obviously a >50% likelihood of it not being good news. I've cut this so many ways for you this past year... it's >50%, it's easily 66% and there's a distinct possibility it's around 86%.
papillon
30/4/2019
22:20
mdalos1 30 Apr '19 - 20:02 - 4410 of 4410 0 0 0 like I've previously said... last year for example... 85% >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Prove it. Oh I forgot, you can't! LOL. The only 85 I remember you posting last year was the 8.5p share price target you had for AMYT.
papillon
Chat Pages: Latest  183  182  181  180  179  178  177  176  175  174  173  172  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 10:00:08